Association between oral intake magnesium and sarcopenia: a cross-sectional study

BMC Geriatrics

Table 4 Association between quartiles of oral intake magnesium and sarcopenia

		Sarcopenia
Models	Quartiles of oral intake magnesium	OR (95% CI)	P Value
Model 1	Q2 v.s. Q1	0.937 (0.701-1.251)	0.658
	Q3 v.s. Q1	0.767 (0.568-1.036)	0.084
	Q4 v.s. Q1	0.400 (0.282-0.568)	< 0.001
Model 2	Q2 v.s. Q1	0.870 (0.635-1.192)	0.387
	Q3 v.s. Q1	0.871 (0.628-1.208)	0.409
	Q4 v.s. Q1	0.615 (0.421-0.900)	0.012
Model 3	Q2 v.s. Q1	0.782 (0.555-1.102)	0.160
	Q3 v.s. Q1	0.767 (0.518-1.134)	0.183
	Q4 v.s. Q1	0.453 (0.267-0.767)	0.003
Model 4	Q2 v.s. Q1	0.775 (0.548-1.097)	0.150
	Q3 v.s. Q1	0.794 (0.534-1.181)	0.255
	Q4 v.s. Q1	0.468 (0.274-0.799)	0.005

BMI Body mass index, CRP C-reactive protein, CI Confidence interval, OR Odds ratio, Q Quartile
Adjusted covariates:
Model 1 = Unadjusted
Model 2 = Adjusted age, sex, race/ethnicity
Model 3 = Model 2 + BMI, Albumin, total calcium, creatinine, fasting glucose, CRP, daily carbohydrate intake, daily total fat intake, and daily protein intake
Model 4 = Model 3 + drinking history, smoking history, comorbidities, and education level

ISSN: 1471-2318